Telmisartan‐enhanced hypercholesterolaemic serum‐induced vascular endothelial growth factor expression in immortalized human umbilical vascular endothelial cells

References

• Rodriguez J. A., Nespereira B., Perez‐Ilzarbe M., Eguinoa E., Paramo J. A. Vitamins C and E prevent endothelial VEGF and VEGFR‐2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovasc Res 2005; 65: 665–73
   PubMedGoogle Scholar
• Wilson S. H., Herrmann J., Lerman L. O., Holmes D. R, Jr., Napoli C., Ritman E. L., et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415–18
   PubMed Web of Science ®Google Scholar
• Trape J., Morales C., Molina R., Filella X., Marcos J. M., Salinas R., et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand J Clin Lab Invest 2006; 66: 261–7
   PubMed Web of Science ®Google Scholar
• Trisciuoglio D., Iervolino A., Zupi G., Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl‐2‐induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005; 16: 4153–62
   PubMedGoogle Scholar
• Marx N., Duez H., Fruchart J. C., Staels B. Peroxisome proliferator‐activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168–78
   PubMed Web of Science ®Google Scholar
• Strawn W. B., Chappell M. C., Dean R. H., Kivlighn S., Ferrario C. M. Inhibition of early atherogenesis by losartan in monkeys with diet‐induced hypercholesterolemia. Circulation 2000; 101: 1586–93
   PubMed Web of Science ®Google Scholar
• Bian C., Zhao K., Tong G. X., Zhu Y. L., Chen P. Immortalization of human umbilical vein endothelial cells with telomerase reverse transcriptase and simian virus 40 large T antigen. J Zhejiang Univ Sci B 2005; 6: 631–6
   PubMedGoogle Scholar
• Zhu Y., Zhong X., Zheng S., Ge Z., Du Q., Zhang S. Transformation of immortalized colorectal crypt cells by microcystin involving constitutive activation of Akt and MAPK cascade. Carcinogenesis 2005; 26: 1207–14
   PubMed Web of Science ®Google Scholar
• Lee I. Y., Kim J., Ko E. M., Jeoung E. J., Kwon Y. G., Choe J. Interleukin‐4 inhibits the vascular endothelial growth factor‐ and basic fibroblast growth factor‐induced angiogenesis in vitro. Mol Cells 2002; 14: 115–21
   PubMed Web of Science ®Google Scholar
• Sugano R., Matsuoka H., Haramaki N., Umei H., Murase E., Fukami K., et al. Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid‐lowering therapies. Arterioscler Thromb Vasc Biol 2005; 25: 1262–7
   PubMed Web of Science ®Google Scholar
• Rodriguez J. A., Grau A., Eguinoa E., Nespereira B., Perez‐Ilzarbe M., Arias R., et al. Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis 2002; 165: 33–40
   PubMed Web of Science ®Google Scholar
• Petnehazy T., Stokes K. Y., Russell J. M., Granger D. N. Angiotensin II type‐1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension 2005; 45: 209–15
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 2005; 46: 179–90
   PubMed Web of Science ®Google Scholar
• Vernon R. B., Sage E. H. A novel, quantitative model for study of endothelial cell migration and sprout formation within three‐dimensional collagen matrices. Microvasc Res 1999; 57: 118–33
   PubMed Web of Science ®Google Scholar
• Kevil C. G., Payne D. K., Mire E., Alexander J. S. Vascular permeability factor/vascular endothelial cell growth factor‐mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 1998; 273: 15099–103
   PubMed Web of Science ®Google Scholar
• Wang W., Dentler W. L., Borchardt R. T. VEGF increases BMEC monolayer permeability by affecting occluding expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001; 280: H434–40
   PubMed Web of Science ®Google Scholar
• Dudley A. C., Thomas D., Best J., Jenkins A. A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J 2005; 390: 427–36
   PubMed Web of Science ®Google Scholar
• Celletti F. L., Waugh J. M., Amabile P. G., Brendolan A., Hilfiker P. R., Dake M. D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425–9
   PubMed Web of Science ®Google Scholar
• Hellwig‐Burgel T., Stiehl D. P., Katschinski D. M., Marxsen J., Kreft B., Jelkmann W. VEGF production by primary human renal proximal tubular cells: requirement of HIF‐1, PI3‐kinase and MAPKK‐1 signaling. Cell Physiol Biochem 2005; 15: 99–108
   PubMedGoogle Scholar
• Eum S. Y., Lee Y. W., Hennig B., Toborek M. VEGF regulates PCB 104‐mediated stimulation of permeability and transmigration of breast cancer cells in human microvascular endothelial cells. Exp Cell Res 2004; 296: 231–44
   PubMedGoogle Scholar
• Graells J., Vinyals A., Figueras A., Llorens A., Moreno A., Marcoval J., et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004; 123: 1151–61
   PubMed Web of Science ®Google Scholar
• Benson S. C., Pershadsingh H. A., Ho C. I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma‐modulating activity. Hypertension 2004; 43: 993–1002
   PubMed Web of Science ®Google Scholar
• Tamarat R., Silvestre J. S., Durie M., Levy B. I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor‐ and inflammation‐related pathways. Lab Invest 2002; 82: 747–56
   PubMed Web of Science ®Google Scholar
• Ruiz‐Ortega M., Lorenzo O., Ruperez M., Suzuki Y., Egido J. Angiotensin II activates nuclear transcription factor‐kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant 2001; 16 Suppl 1: 27–33
   PubMedGoogle Scholar
• Miyajima A., Kosaka T., Asano T., Asano T., Seta K., Kawai T., et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62: 4176–9
   PubMed Web of Science ®Google Scholar
• Tamarat R., Silvestre J. S., Kubis N., Benessiano J., Duriez M., deGasparo M., et al. Endothelial nitric oxide synthase lies downstream from angiotensin II‐induced angiogenesis in ischemic hindlimb. Hypertension 2002; 39: 830–5
   PubMedGoogle Scholar
• Murakami Y., Kurosaki K., Matsui K., Shimada K., Ikeda U. Serum MCP‐1 and VEGF levels are not affected by inhibition of the renin‐angiotensin system in patients with acute myocardial infarction. Cardiovasc Drugs Ther 2003; 17: 249–55
   PubMedGoogle Scholar
• Hsueh W. A., Bruemmer D. Peroxisome proliferator‐activated receptor gamma: implications for cardiovascular disease. Hypertension 2004; 43: 297–305
   PubMed Web of Science ®Google Scholar
• Barroso I., Gurnell M., Crowley V. E., Agostini M., Schwabe J. W., Soos M. A., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–3
   PubMed Web of Science ®Google Scholar
• Kanata S., Akagi M., Nishimura S., Hayakawa S., Yoshida K., Sawamura T., et al. Oxidized LDL binding to LOX‐1 upregulates VEGF expression in cultured bovine chondrocytes through activation of PPAR‐gamma. Biochem Biophys Res Commun 2006; 348: 1003–10
   PubMed Web of Science ®Google Scholar
• Yang B., Lin P., Carrick K. M., McNulty J. A., Clifton L. G., Winegar D. A., et al. PPARgamma agonists diminish serum VEGF elevation in diet‐induced insulin resistant SD rats and ZDF rats. Biochem Biophys Res Commun 2005; 334: 176–82
   PubMedGoogle Scholar
• Nagai N., Oike Y., Izumi‐Nagai K., Urano T., Kubota Y., Noda K., et al. Angiotensin II type 1 receptor‐mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006; 26: 2252–9
   PubMed Web of Science ®Google Scholar